Montelukast Accord (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Accord, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as maintenance therapy.

GNH USA supplies Montelukast Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control inflammatory airway conditions.

Asthma: reduces frequency of wheezing episodes and improves lung function. Allergic rhinitis: alleviates nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Nausea - Cough - Sore throat - Fatigue

Serious or Rare Side Effects: - Angioedema or anaphylaxis - Mood changes, including depression or suicidal thoughts - Elevated liver enzymes - Severe rash or Stevens‑Johnson syndrome - Eosinophilic pneumonia - Hematologic abnormalities

Before prescribing Montelukast, clinicians should consider several safety aspects.

Assess asthma control before initiating: ensure patient is on appropriate inhaled therapy. Monitor for neuropsychiatric symptoms: report mood changes, depression, or suicidal thoughts. Use caution in patients with hepatic impairment: adjust if needed. Avoid use in patients with known hypersensitivity to montelukast or any excipient. Consider drug interactions: review concomitant medications. Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Montelukast may interact with several medicines; awareness of interaction severity helps guide monitoring.

Major Interactions (Avoid): - Phenobarbital: may reduce plasma concentrations of montelukast. - Rifampin: may decrease effectiveness of montelukast. - Ketoconazole: may increase montelukast levels, raising risk of side effects.

Moderate Interactions (Monitor Closely): - Warfarin: may alter INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilation effect; observe clinical response. - Antidepressants (SSRIs): monitor for neuropsychiatric events.